NICE does not recommend Novartis' Rydapt for AML

The U.K.'s NICE issued draft guidance recommending against the use of Rydapt midostaurin (CGP 41251, PKC412) from Novartis AG (NYSE:NVS; SIX:NOVN)

Read the full 211 word article

User Sign In